Clinical trials: Pelvic Neoplasms
Abdominal Cancer, Pelvic Cancer
Ablative Stereotactic MR-Guided Adaptive Reirradiation
This research study will enroll people who have cancer in their abdomen or pelvis that was treated previously with radiation therapy.
- Trial name
- NCT06397573
- Testing
- Reirradiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baptist Health South Florida
Polycystic Ovary Syndrome (PCOS), Menstrual Symptoms
Mindfulness-Based Education For Women With Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS), also known as polyendocrine metabolic ovarian syndrome (PMOS), is the most common endocrinologic disorder to affect women. Despite this, the disease's pathophysiology remains unclear.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Menstrual Symptoms, Stress, Quality of Life
- Trial name
- NCT07718217
- Testing
- Mindfulness-Based Polycystic Ovary Syndrome (PCOS) Education
- Where
- Turkey (Türkiye)
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Cervical Carcinoma
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression.
- Trial name
- STIRR (NCT06804135)
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Tata Memorial Hospital
Urothelial Cancer, Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Plus EV in Metastatic UC
Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC).
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Trial name
- NCT04724018
- Testing
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Dana-Farber Cancer Institute
Rectal Cancer, Neoplasm Metastasis
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Panitumumab is a monoclonal antibody. It works by attaching to a protein called epidermal growth factor receptor found on normal and cancer cells.
- Trial name
- NCT00346099
- Testing
- Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation
- Sponsor
- NSABP Foundation Inc
Prostate Cancer, Bladder Cancer
A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer
Radical radiation therapy for prostate cancer is a common treatment that has shown to improve clinical outcomes in a post-operative setting.
- Trial name
- ARTGU (NCT03909893)
- Testing
- Adaptive Radiation Therapy
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Lower Abdominal Surgery, Pelvic Surgery
Objective to Evaluate the Safety and Effectiveness of LED Light Source System for Endoscopy in Ureteral Radiography
This clinical trial is a prospective, multi-center, single-blind, parallel, randomized controlled superiority clinical trial. The trial will be carried out in 5 centers, involving 120 subjects as estimated who will be divided…
- Trial name
- IRIS (NCT04561414)
- Testing
- LED light source system for endoscope, Ureteral stent (Cook Ireland Ltd.)
- Where
- 4 sites in China
- Sponsor
- Stryker Orthopaedics
Abnormal Uterine Bleeding, Uterine Bleeding
Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy
The purpose of the study is to investigate differences in perioperative and postoperative outcomes between the abdominal (AM) versus vaginal (VM) routes of contained morcellation in participants undergoing laparoscopic total…
- Conditions
- Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
- Trial name
- NCT04434066
- Testing
- Total Laparoscopic Hysterectomy
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
Hyperbaric Oxygenation Treatment and Quality of Life
Osteoradionecrosis, dermal soft tissue necrosis, radiation cystitis, proctitis and sexual dysfunctions are well-known late-effects after radiation for cancer in the pelvic area, negatively affecting the survivors' quality of life…
- Trial name
- NCT03570229
- Testing
- Hyperbaric oxygen treatment
- Where
- Norway
- Volunteers
- 137 people
- Sponsor
- University of Bergen
Abdominal Cancer
Vessel- and Bone-based Ultrasound Registration
In this study we aim to develop an automatic artery and bone segmentation algorithm, which is required for future clinical implementation of US registration for surgical navigation.
- Trial name
- NCT05637346
- Testing
- Intra-operative ultrasound measurement
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Adenocarcinoma of Prostate, Progression of Prostate Cancer
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
The objective of this study is to assess the effect of neoadjuvant cabazitaxel and pelvic radiotherapy in combination with androgen deprivation therapy (ADT)-radiotherapy on clinical progression-free survival in patients with…
- Trial name
- PEACE2 (NCT01952223)
- Testing
- Cabazitaxel, Pelvic radiotherapy, prostate radiotherapy
- Where
- France
- Volunteers
- 761 people
- Sponsor
- UNICANCER
Chronic Pain
Analgesic Efficacy of Sacral Neuromodulation for Pelvic Cancer Pain: A Preliminary Report
in this trial, we will test the analgesic efficacy of sacral neuromodulation for patients with pelvic cancer, complaining of chronic pelvic pain in comparison to medical treatment.
- Trial name
- NCT04549818
- Testing
- sacral neuromodulation
- Volunteers
- 44 people
- Sponsor
- Assiut University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic…
- Trial name
- NCT00066352
- Testing
- bortezomib
- Where
- 15 sites in United States, Canada
- Sponsor
- University Health Network, Toronto
Prostate Cancer (Post Prostatectomy), Urinary Incontinence (UI)
The Effect of Pelvic Floor Muscle Exercises After Radical Prostatectomy
Cancer, a major public health problem worldwide, was one of the leading causes of mortality in 2020, accounting for approximately 10 million deaths.
- Trial name
- NCT07045415
- Testing
- Pelvic Floor Muscle Exercises.
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people
- Sponsor
- KTO Karatay University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022633
- Testing
- gemcitabine hydrochloride, paclitaxel
- Where
- 92 sites in United States
- Volunteers
- 65 people
- Sponsor
- SWOG Cancer Research Network
Adnexal Mass
New Biomarkers Evaluating Ovarian Cancer
The purpose of this study is to evaluate new biomarkers for patients presenting to a physician for surgery to remove a mass in their pelvis and to continue to evaluate these types of patients using the ROMA algorithm for…
- Trial name
- NCT01466049
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- Fujirebio Diagnostics, Inc.
Thoracic Neoplasm, Pelvic Neoplasm
Oncologic Therapy Support Via Means of a Dedicated Mobile App
The present single-center prospective exploratory study, conducted at Heidelberg University Hospital, assesses the feasibility of introducing a concept for additional patient care based on a mobile application for patients…
- Conditions
- Thoracic Neoplasm, Pelvic Neoplasm, Radiotherapy; Complications, Oncologic Disorders
- Trial name
- OPTIMISE-1 (NCT03168048)
- Testing
- mobile application
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Healthy Participants, Pelvic Neoplasms
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
This study will help to elucidate the treatment sites in the extremities and pelvis for which MR-guided HIFU heating is feasible, which has the potential to be beneficial for patients with conditions at those sites (soft tissue…
- Conditions
- Healthy Participants, Pelvic Neoplasms, Soft-tissue Sarcoma, Bladder Cancer
- Trial name
- NCT03007771
- Testing
- Magnetic Resonance-guided High-Intensity Focused Ultrasound
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Pelvis Neoplasms
Pelvis Adaptive Radiotherapy (ART)
Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region.
- Trial name
- Pelvis ART (NCT06650033)
- Testing
- Adaptive radiotherapy +/- margin reduction, Image guided radiotherapy
- Where
- Australia
- Volunteers
- 280 people
- Sponsor
- Royal North Shore Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00005958
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in United States
- Sponsor
- Amgen